Abstract Body

Background:

In 2019, WHO recommended dolutegravir (DTG) for first- and second-line antiretroviral therapy (ART) regimens for people living with HIV (PLHIV). Per Uganda treatment guidelines, patients with virologic non-suppression (≥1,000 copies/mL) should receive intensive adherence counseling (IAC) with repeat VL within 6 months. This evaluation analyzed prevalence and factors contributing to suppression following programmatic routine IAC among PLHIV on DTG based regimens with virologic failure in Uganda.

Methods:

We conducted a retrospective analysis on virologic non-suppressed (≥1,000 copies/mL) PLHIV on DBRs during October 2019–September 2020 who had a follow up VL test result, presumably following routine programmatic IAC. Data were abstracted from the Central Public Health Laboratory (CPHL), including patient demographics and test results. Suppression was defined as a VL test result of < 1,000 copies/mL at follow up given a previous result of ≥1,000 copies/mL. We characterized PLHIV on DBRs and used logistic regression models to assess factors (e.g., sex, age) associated with suppression.

Results:

We analyzed 521 PLHIV on DBRs with virologic non-suppression who had a follow up VL test. Of these, 220 (42.2%) were children < 15 years and 231 (44.3%) were female. Median age was 28 years (interquartile range [IQR]: 12–43 years), and median duration on DBRs was 12 months (IQR: 6–15 months). Overall, 80.8% (421/521) PLHIV suppressed at the follow up VL test (children = 74.5% [164/220]; adults = 85.4% [257/301]). Compared to adults, children < 15 years were less likely to achieve suppression (Odds Ratio [OR]: 0.5; 95% Confidence Interval [CI]: 0.32–0.78, p=0.002). PLHIV with initial VL results ≥5,000 copies/mL were less likely to achieve virologic suppression at follow up testing compared to those with < 5000 copies/mL. (OR: 0.44; 95% CI: 0.29–0.84, p < 0.001).

Conclusions:

Majority of adults and children with virologic failure achieved viral suppression following routine programmatic IAC as per the national treatment guidelines. Additional specialized support is needed for younger age groups and those with high VL results at first test.